Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

de Heer, EC; Zois, CE; Bridges, E; van der Vegt, B; Sheldon, H; Veldman, WA; Zwager, MC; van der Sluis, T; Haider, S; Morita, T; Baba, O; Schröder, CP; de Jong, S; Harris, AL; Jalving, M

Women's Health Collection

Journal article

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

Abstract:: BACKGROUND: Hypoxia-induced glycogen turnover is implicated in cancer proliferation and therapy resistance. Triple-negative breast cancers (TNBCs), characterized by a hypoxic tumor microenvironment, respond poorly to therapy. We studied the expression of glycogen synthase 1 (GYS1), the key regulator of glycogenesis, and other glycogen-related enzymes in primary tumors of patients with breast cancer and evaluated the impact of GYS1 downregulation in preclinical models. METHODS: mRNA expression of GYS1 and other glycogen-related enzymes in primary breast tumors and the correlation with patient survival were studied in the METABRIC dataset (n = 1904). Immunohistochemical staining of GYS1 and glycogen was performed on a tissue microarray of primary breast cancers (n = 337). In four breast cancer cell lines and a mouse xenograft model of triple-negative breast cancer, GYS1 was downregulated using small-interfering or stably expressed short-hairpin RNAs to study the effect of downregulation on breast cancer cell proliferation, glycogen content and sensitivity to various metabolically targeted drugs. RESULTS: High GYS1 mRNA expression was associated with poor patient overall survival (HR 1.20, P = 0.009), especially in the TNBC subgroup (HR 1.52, P = 0.014). Immunohistochemical GYS1 expression in primary breast tumors was highest in TNBCs (median H-score 80, IQR 53-121) and other Ki67-high tumors (median H-score 85, IQR 57-124) (P < 0.0001). Knockdown of GYS1 impaired proliferation of breast cancer cells, depleted glycogen stores and delayed growth of MDA-MB-231 xenografts. Knockdown of GYS1 made breast cancer cells more vulnerable to inhibition of mitochondrial proteostasis. CONCLUSIONS: Our findings highlight GYS1 as potential therapeutic target in breast cancer, especially in TNBC and other highly proliferative subsets.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

de Heer, E. C., Zois, C. E., Bridges, E., van der Vegt, B., Sheldon, H., Veldman, W. A., Zwager, M. C., van der Sluis, T., Haider, S., Morita, T., Baba, O., Schröder, C. P., de Jong, S., Harris, A. L., & Jalving, M. (2023). Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer. Journal of Experimental & Clinical Cancer Research, 42(1), 143–143.

MLA Style

de Heer, EC, et al. “Glycogen Synthase 1 Targeting Reveals a Metabolic Vulnerability in Triple-Negative Breast Cancer.” Journal of Experimental & Clinical Cancer Research, vol. 42, no. 1, 2023, pp. 143–43.

Chicago Style

Heer, EC de, CE Zois, E Bridges, et al. 2023. “Glycogen Synthase 1 Targeting Reveals a Metabolic Vulnerability in Triple-Negative Breast Cancer.” Journal of Experimental & Clinical Cancer Research 42 (1): 143–43.
Print